Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease

被引:27
作者
McCullough, Peter A. [1 ,2 ,3 ]
Verrill, Thomas A.
机构
[1] William Beaumont Hosp, Dept Med, Div Cardiol, Royal Oak, MI 48073 USA
[2] William Beaumont Hosp, Dept Med, Div Nutr, Royal Oak, MI 48073 USA
[3] William Beaumont Hosp, Dept Med, Div Prevent Med, Royal Oak, MI 48073 USA
关键词
chronic kidney disease; cardiovascular disease; renin-angiotensin-aldosterone system blockade; risk factors; PERCUTANEOUS CORONARY INTERVENTION; CONVERTING ENZYME-INHIBITORS; TYPE-2; DIABETES-MELLITUS; LEFT-VENTRICULAR HYPERTROPHY; ACUTE MYOCARDIAL-INFARCTION; INTENSIVE GLUCOSE CONTROL; BLOOD-PRESSURE RESEARCH; EVALUATION PROGRAM KEEP; LOW-DOSE ASPIRIN; RENAL-INSUFFICIENCY;
D O I
10.3810/pgm.2010.03.2119
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease (CKD) is a recognized risk multiplier for the development of cardiovascular disease (CVD), with CVD events representing the leading cause of morbidity and mortality in patients with CKD. The nature of CKD as a risk state relates both to the nature of CKD and the antecedent development of CVD. In addition, patients with CKD have increased rates of multiple conventional cardiac risk factors. Although early data regarding the relationship between CVD and CKD were limited because of the need for large data sets and multivariable analysis, the importance of recognizing this complex relationship is now clear. The essence of the relationship appears to be bidirectional, and therapy directed at improving natural history of chronic disease on one system generally improves prognosis in the other. Specifically, CVD outcomes have been shown to improve with the treatment of risk factors commonly found in association with CKD, including hypertension, diabetes, dyslipidemia, albuminuria, and smoking, as well as appropriate renin-angiotensin-aldosterone system blockade and antiplatelet therapy. Once hospitalized, management of acute coronary syndromes represents a key area of clinical investigation. The goal of this article is to highlight the importance of these topics in improving cardiovascular outcomes and use of appropriate treatment in CKD.
引用
收藏
页码:25 / 34
页数:10
相关论文
共 110 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]   Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States [J].
Agarwal, R ;
Nissenson, AR ;
Batlle, D ;
Coyne, DW ;
Trout, JR ;
Warnock, DG .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 (04) :291-297
[3]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[4]   Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials [J].
Allemann, S ;
Diem, P ;
Egger, M ;
Christ, ER ;
Stettler, C .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (03) :617-623
[5]  
Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
[6]  
[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001837.1)UB2
[7]   Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals -: The Framingham heart study [J].
Ärnlöv, J ;
Evans, JC ;
Meigs, JB ;
Wang, TJ ;
Fox, CS ;
Levy, D ;
Benjamin, EJ ;
D'Agostino, RB ;
Vasan, RS .
CIRCULATION, 2005, 112 (07) :969-975
[8]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[9]   Role for β-blockers in the management of diabetic kidney disease [J].
Bakris, GL .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (09) :7S-12S
[10]   Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis [J].
Berger, Jeffrey S. ;
Brown, David L. ;
Becker, Richard C. .
AMERICAN JOURNAL OF MEDICINE, 2008, 121 (01) :43-49